



- (51) International Patent Classification:
A61B 17/56 (2006.01)
- (21) International Application Number:
PCT/US2013/058877
- (22) International Filing Date:
10 September 2013 (10.09.2013)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
61/699,089 10 September 2012 (10.09.2012) US
- (71) Applicant: **COTERA, INC.** [US/US]; 199 Jefferson Drive,
Menlo Park, CA 94025 (US).
- (72) Inventor: **SHENOY, Vivek**; 199 Jefferson Drive, Menlo
Park, CA 94025 (US).
- (74) Agent: **KOHLER, Thomas, D.**; Downs Rachlin Martin
PLLC, 199 Main Street, P.O. Box 190, Burlington, VT
05402-0190 (US).
- (81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,

[Continued on next page]

(54) Title: METHOD AND APPARATUS FOR TREATING CANINE CRUCIATE LIGAMENT DISEASE

(57) Abstract: Protheses and methods for treating canine cruciate ligament disease are disclosed comprising placement of a specifically configured implant on the femur or tibia to displace targeted muscle or connective tissue associated with the stifle joint so as to reduce cranial tibial thrust.




FIG. 9



TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

METHOD AND APPARATUS FOR TREATING CANINE CRUCIATE LIGAMENT DISEASE

FIELD OF THE INVENTION

[0001] The present invention generally relates to the field of veterinary orthopedic disease. In particular, the present invention is directed to an interventional technique and an implant for treating canine cruciate ligament disease.

BACKGROUND

[0002] Cruciate ligament degeneration or rupture is a common canine disease. The cruciate ligaments are the primary stabilizing structures of canine stifle joint. The canine stifle joint is condylar synovial joint. The primary motion of joint is flexion and extension. The three major muscles comprising the caudal thigh group are the biceps femoris, the semitendinosus and the semimembranosus, also collectively known as the hamstring muscles. The bones, muscles, tendons, ligaments etc. of the canine stifle joint are shown in detail in Figures 1 – 6 (Reference: Carpenter, D.H. et al, Mini Review of Canine Stifle Joint Anatomy, *Anat. Histol. Embryol.*, **29**, 321-329, 2000).

[0003] A cranial view of the left stifle showing associated ligaments and structures is shown in Figure 1. The following features are identified: 1A, femoral trochlea; 2A, lateral ridge of femoral trochlea; 3A, tendon of long digital extensor; 4A, tendon of popliteus; 5A, lateral collateral ligament; 6A, lateral meniscus; 7A, tibial tuberosity; 8A, patellar ligament; 9A, patella; 10A, parapatellar fibrocartilage; 11A, intermeniscal ligament; 12A, medial meniscus; 13A, medial collateral ligament; 14A, cranial cruciate ligament; 15A, caudal cruciate ligament; 16A, medial ridge of the trochlea.

[0004] A caudal view of the right stifle showing associated ligaments and structures is shown in Figure 2. The following features are identified: 1B, cranial cruciate ligament; 2B, lateral collateral ligament, 3B, lateral meniscus; 4B, cranial ligament of the fibular head; 5B, caudal ligament of the fibular head; 6B, fibula; 7B,

caudal meniscotibial ligament of the lateral meniscus; 8B, caudal cruciate ligament; 9B, medial meniscus; 10B, medial collateral ligament; 11B, meniscofemoral ligament.

[0005] A lateral view of the right stifle showing associated ligaments and structures is shown in Figure 3. The following features are identified: 1C, popliteus tendon; 2C, lateral collateral ligament; 3C, sesamoid; 4C, lateral femoropatellar ligament; 5C, quadriceps muscle group tendon of insertion; 6C, patella; 7C, patellar ligament; 8C, lateral meniscus; 9C, tibial tuberosity; 10C, tibial crest; 11C, long digital extensor tendon of origin; 12C, cranial ligament of fibular head; 13C, fibula; 14C, tibia; 15C, os femoris.

[0006] A medial view of the right stifle showing associated ligaments and structures is shown in Figure 4. The following features are identified: 1D, os femoris; 2D, medial femoropatellar ligament; 3D, sesamoid; 4D, medial collateral ligament; 5D, popliteus tendon of origin; 6D, cranial ligament of the fibular head; 7D, fibula; 8D, tibia; 9D, tibial crest; 10D, tibial tuberosity; 11D, patellar ligament; 12D, medial meniscus; 13D, patella; 14D, quadriceps muscle group tendon of insertion.

[0007] A medial view of the left pelvic limb muscles and associated structures is shown in Figure 5. The following features are identified: 1E, cranial sartorius; 2E, caudal sartorius; 3E, cranial tibial; 4E, deep digital flexor; 5E, tibia; 6E, common calcanean tendon; 7E, superficial digital flexor; 8E, gastrocnemius; 9E, biceps femoris tendon of insertion; 10E, semitendinosus, 11E, gracilis; 12E, pectineus; 13E, vastus medialis; 14E, adductor magnus et brevis; 15E, semimembranosus.

[0008] A lateral view of the right pelvic limb muscles and associated structures is shown in Figure 6. The following features are identified: 1F, middle gluteal; 2F, tensor fasciae latae; 3F, cranial sartorius; 4F, vastus lateralis; 5F, cranial tibial; 6F, gastrocnemius; 7F, superficial digital flexor; 8F, long digital extensor; 9F, common calcanean tendon; 10F, biceps femoris tendon of insertion; 11F, caudal head of biceps femoris; 12F, cranial head of biceps femoris; 13F, semitendinosus; 14F, semimembranosus; 15F, superficial gluteal.

[0009] The cranial cruciate ligament (CrCL) prevents cranial tibial translation or the tibial forward thrust, limits excessive internal rotation of the tibia and prevents hyper extension of the stifle. During the stance phase (weight bearing phase) of the gait cycle, loading of the stifle joint leads to a ventrally directed compressive force, and a horizontally directed force, or a cranial tibial thrust. In an intact stifle, the CrCL resists this force, minimizing any cranial translation of the tibia. In a CrCL deficient stifle, the lack of the stabilizing force, leads to cranial translation of the tibia during the weight bearing phase of the gait cycle. The translation of the tibia during the stance phase can alter the load distribution within the stifle joint, leading to pain, stiffness and osteoarthritis of the joint.

[0010] Common surgical treatment options for cruciate ligament disease are Tibial Plateau Levelling Osteotomy (TPLO) and Tibial Tuberosity Advancement (TTA). In a TPLO surgery, illustrated in Figure 7, a semi-circular cut is made on the dorsal end of the tibia. The tibial articular surface is then rotated and stabilized using bone plates and screws. By levelling the tibial plateau, cranial slippage of the tibia during the stance phase is prevented. In a TTA surgery, illustrated in Figure 8, the attachment site of the patellar tendon to the tibia is moved forward by cutting the tibial tuberosity and repositioning it with bone plates and screws.

[0011] TPLO and TTA both carry a risk of failure due to poor bone healing after the osteotomy, as well as a risk of failure due to fracture of the bone weakened by the osteotomy. Moreover, these surgeries require significant pain management following surgery and entail long recovery times.

SUMMARY OF DISCLOSURE

[0012] Exemplary methods disclosed herein comprise selecting at least one of the muscles and connective tissues associated with the canine stifle joint as target tissue for treatment, and displacing the target tissue without severing the bones or target tissue, thereby achieving a therapeutic effect.

[0013] In exemplary embodiments, the target tissue is displaced by placing an implant in contact with the target tissue and displacing the target tissue to reduce cranial tibial thrust. The implant may be secured to a bone and/or to soft tissues, which may include the target tissue. In one exemplary embodiment, the implant is completely outside the capsule surrounding the joint.

[0014] In one exemplary embodiment of the invention, a method for treating canine cruciate ligament disease comprises securing an implant on the medial side of the femur and displacing connective tissue caudal to the femur.

[0015] In one exemplary embodiment of the invention, a method for treating canine cruciate ligament disease comprises securing an implant on the medial side of the femur and displacing connective tissue cranial to the femur.

[0016] In one exemplary embodiment of the invention, a method for treating canine cruciate ligament disease comprises securing an implant on the lateral side of the femur and displacing connective tissue caudal to the femur.

[0017] In one exemplary embodiment of the invention, a method for treating canine cruciate ligament disease comprises securing an implant on the lateral side of the femur and displacing connective tissue cranial to the femur.

[0018] In one exemplary embodiment of the invention, a method for treating canine cruciate ligament disease comprises securing an implant on the caudal side of the femur and displacing connective tissue caudal to the femur.

[0019] In one exemplary embodiment of the invention, a method for treating canine cruciate ligament disease comprises securing an implant on the cranial side of the femur and displacing connective tissue cranial to the femur.

[0020] In one exemplary embodiment of the invention, a method for treating canine cruciate ligament disease comprises securing an implant on the lateral side of the tibia and displacing connective tissue caudal to the tibia.

[0021] In one exemplary embodiment of the invention, a method for treating canine cruciate ligament disease comprises securing an implant on the medial side of the tibia and displacing connective tissue caudal to the tibia.

[0022] In one exemplary embodiment of the invention, a method for treating canine cruciate ligament disease comprises securing an implant on the lateral side of the tibia and displacing connective tissue cranial to the tibia.

[0023] In one exemplary embodiment of the invention, a method for treating canine cruciate ligament disease comprises securing an implant on the medial side of the tibia and displacing connective tissue cranial to the tibia.

[0024] In one exemplary embodiment of the invention, a method for treating canine cruciate ligament disease comprises securing an implant on the caudal side of the tibia and displacing connective tissue caudal to the tibia.

[0025] In one exemplary embodiment of the invention, the target connective tissue is the quadriceps muscle or tendon.

[0026] In one exemplary embodiment of the invention, the target connective tissue is the patellar tendon.

[0027] In one exemplary embodiment of the invention, the target connective tissue is the biceps femoris muscle or tendon.

[0028] In one exemplary embodiment of the invention, the target connective tissue is the semitendinosus muscle or tendon.

[0029] In one exemplary embodiment of the invention, the target connective tissue is the semimembranosus muscle or tendon.

[0030] In one exemplary embodiment of the invention, the quadriceps muscle or tendon is displaced cranially.

[0031] In one exemplary embodiment of the invention, the patellar tendon is displaced cranially.

[0032] In one exemplary embodiment of the invention, the biceps femoris muscle or tendon is displaced caudally.

[0033] In one exemplary embodiment of the invention, the semitendinosus muscle or tendon is displaced caudally.

[0034] In one exemplary embodiment of the invention, the semimembranosus muscle or tendon is displaced caudally.

[0035] One of the exemplary methods disclosed herein comprises selecting at least one of the associated muscle and connective tissues as target tissue for treatment, displacing the target tissue without severing the bones or target tissue, and reducing cranial tibial thrust to achieve a therapeutic effect. The apparatus may be completely outside the capsule surrounding the stifle joint or may be in contact with the exterior of the capsule.

[0036] By using the implants of the invention, appropriately sized and positioned as described herein, displacement of targeted connective and muscle tissues surrounding the joint is accomplished in order to realign force vectors and/or alter moment arms loading the joint to achieve therapeutic effects without cutting bone and with minimal cutting of the connective tissues. Alternative and more specific devices and methodologies are described in more detail herein below.

BRIEF DESCRIPTION OF DRAWINGS

[0037] For the purpose of illustrating the invention, the drawings show aspects of one or more exemplary embodiments of the invention. However, it should be understood that the present invention is not limited to the precise arrangements and instrumentalities shown in the drawings, wherein:

[0038] FIG. 1 is the cranial view of a left canine stifle joint showing ligaments and associated structures.

[0039] FIG. 2 is the caudal view of a right canine stifle joint showing ligaments and associated structures.

[0040] FIG. 3 is the lateral view of a right canine stifle joint showing ligaments and associated structures.

[0041] FIG. 4 is the medial view of a right canine stifle joint showing ligaments and associated structures.

[0042] FIG. 5 is the medial view of a left canine pelvic limb showing muscles and associated structures.

[0043] FIG. 6 is the lateral view of a right canine pelvic limb showing muscles and associated structures.

[0044] FIG. 7 is a schematic representation of Tibial Plateau Levelling Osteotomy.

[0045] FIG. 8 is a schematic representation of Tibial Tuberosity Advancement osteotomy.

[0046] FIG 9 is a cranial view of a left canine stifle joint illustrating positioning of an exemplary embodiment of the present invention for treating cruciate ligament disease.

[0047] FIG 10 is a cranial view of a left canine stifle joint illustrating positioning of another exemplary embodiment of the present invention for treating cruciate ligament disease.

[0048] FIG 11 is a medial view of a right canine stifle joint illustrating positioning of a further exemplary embodiment of the present invention for treating cruciate ligament disease.

[0049] FIG 12 is a lateral view of a right canine stifle joint illustrating positioning of yet another exemplary embodiment of the present invention for treating cruciate ligament disease.

[0050] FIG 13 is a medial view of a right canine stifle joint illustrating positioning of another exemplary embodiment of the present invention for treating cruciate ligament disease.

[0051] FIG 14 is a medial view of a right canine stifle joint illustrating positioning of another exemplary embodiment (#600) of the present invention for treating cruciate ligament disease.

[0052] FIG 15 is a lateral view of a right canine stifle joint illustrating positioning of another exemplary embodiment of the present invention for treating cruciate ligament disease.

[0053] FIG 16 is a caudal view of a right canine stifle joint illustrating positioning of another exemplary embodiment of the present invention for treating cruciate ligament disease.

[0054] FIG 17 is a caudal view of a right canine stifle joint illustrating positioning of another exemplary embodiment of the present invention for treating cruciate ligament disease.

[0055] FIG 18 is a caudal view of a right canine stifle joint illustrating positioning of another exemplary embodiment of the present invention for treating cruciate ligament disease.

[0056] FIG 19 is a cranial view of a left canine stifle joint illustrating positioning of another exemplary embodiment of the present invention for treating cruciate ligament disease.

[0057] FIG 20 is a cranial view of a left canine stifle joint illustrating positioning of another exemplary embodiment of the present invention for treating cruciate ligament disease.

DETAILED DESCRIPTION

[0058] Utilizing embodiments of the present invention, joint conditions that result from or exacerbate unbalanced force distribution through the joint may be addressed by interventional techniques involving a redistribution of forces exerted on the joint without the need for highly invasive surgeries requiring significant trauma to the joint and associated muscle and connective tissues. Redistribution of forces within the target joint in accordance with embodiments described herein may thus provide pain relief or slow down articular cartilage degeneration or enhance cartilage regeneration.

[0059] In some embodiments of the invention, increased forces can be selectively applied to one side of a joint by routing select muscle, tendons, ligaments, and/or other connective tissues (target tissues) around a longer, curved, or more angled path, thus increasing the magnitude, altering the effective direction, and/or changing the moment arm of forces exerted by such muscles or tissues on the joint. This may be accomplished, for example, by appropriately shaped implants that may be positioned to displace selected target tissues relatively non-invasively compared to current surgical techniques for addressing such conditions. The amount of displacement of the target tissue may not need to be large in order to provide a substantial therapeutic effect on the target joint. Depending upon the nature of the disease and the size and geometry of the particular canine joint, displacements of greater than about 2 mm up to about 25 mm may be sufficient, with displacements in the range of about 3 mm to about 20 mm also suitable, or more specifically about 4 – 15 mm.

[0060] Exemplary embodiments of the invention described herein are particularly directed to treatment of canine cruciate ligament disease, although the principles of the invention may be applied to other canine or human articular joints as described in the above identified related applications of the present provisional application, which as stated above are incorporated by reference herein. In general, it will be appreciated by persons of ordinary skill in the art that specific features described in connection with one exemplary embodiment may be incorporated in other exemplary embodiments unless otherwise noted. The exemplary embodiments described are thus included to illustrate features of the invention, not limit it.

[0061] As used herein, “therapeutic effect” means an effect on a treated joint that reduces forces acting on the articular surfaces, reduces abnormal motion of the bones during flexion/extension, reduces wear, lessens pain or provides another positive outcome for the patient whether across the joint as a whole or in particular parts of the joint. In the canine stifle joint, therapeutic effect would generally be associated with a reduction in cranial tibial thrust. “Therapeutic effect,” however, does not imply, and should not be understood as requiring, any specific, quantified outcome other than as stated above.

[0062] As used herein, dorsal means directed towards the back, ventral means directed towards the belly, medial means directed towards the mid-line, lateral means directed away from the mid-line towards the flank, cranial means directed towards the cranium (head) and caudal towards the tail. Proximal refers to the end of a structure nearest a major point of reference and distal to the end furthest from a point of reference. The point of reference is usually the origin of a structure (such as a limb). Dorsal plane is parallel to the back, transverse plane is perpendicular to the long axis of the body and sagittal plane divides the body into right/left parts.

[0063] Implants according to embodiments of the present invention may be configured and secured in a variety of ways as described below in more detail with respect to exemplary embodiments. However, in general, and with reference to implant 100 shown in Figure 9, prostheses or implants according to embodiments of the invention may comprise a fixation portion 101 configured to be secure to the bone at a specific location, and which may provide means for securing or anchoring the prosthesis, such as holes for bone screws 110, and a displacement portion 103 configured and dimensioned to displace the target tissue(s) from a pretreatment path as described herein. Other means for securing the fixation portion may include bone ingrowth surfaces, barbs, bone cement, features for fastening sutures or wires, and other devices known in the art for securing implants to bone. The fixation and displacement portions may be separated by a spanning section 102 configured and dimensioned to position the displacement portion with respect to the fixation portion as appropriate to accommodate the anatomical structures at the location of treatment and fixation. For example, the spanning section may be configured to avoid tendon attachment sites between the fixation and

displacement region. The displacement portion 102 may be provided with a bearing member for engaging the target tissue, which may be the same or a different material than the underlying substrate.

[0064] Depending on the mechanical load on the implant, and the choice of material or materials used to fabricate the implant, thickness of the fixation portion. The thickness of the fixation portion of the implant may be uniform throughout the implant or may vary across the implant. Regions of the fixation portion under higher mechanical load may be thicker than regions under lower mechanical loads. The thickness of the fixation region may also be selected to ensure that the screw-heads used to fix the implant do not protrude over the surface of the implant.

[0065] The spanning section may have thickness similar to that of the fixation portion. Persons of ordinary skill in the art will appreciate that a principal consideration for spanning section is sufficient structural integrity to maintain the displacement portion at the desired treatment position. In the displacement portion, displacement distance and thickness may be considered separately. Displacement distance is the distance by which the bearing surface of the displacement portion displaces the target tissue beyond the natural anatomical track of the target tissue, in other words, the displacement of tissue created by the implant. Depending on the particular geometry of the implant, the thickness of the displacement portion may or may not be related to the displacement distance.

[0066] In alternative embodiments, components of the prosthesis may be a compliant material such as an elastomer, capsules filled with water, saline, silicone, hydrogels, etc. Embodiments with compliant portions could be placed in a deflated state and then inflated to the appropriate thickness. Alternatively, bearing members may be filled with other flowable materials including beads or other particles made of metal, polymer, or foam material, optionally in a liquid medium, which conform to the adjacent bone or tissue surfaces. Thixotropic materials, such as hydrogels derived from hyaluronic acid, change their mechanical properties as shear stress is applied to them. An implant filled with such materials could be made to change the amount of displacement that it provides

based on the shear stress that it sees from overlying target tissues at various points in the gait cycle. Implants may be coated with materials to reduce friction such as hydrophilic coatings or polytetrafluoroethylene (PTFE) coatings. Additionally or alternatively, the prosthesis may be adjustable to allow the dimensions such as thickness of the prosthesis to be adjusted during surgery or any time after surgery.

[0067] Rigid or substantially rigid prostheses according to embodiments of the invention described herein could be made of known bone-compatible implant materials such as titanium or stainless steel. Biocompatible polymers, ceramics, and other materials may also be used. The bearing surface of the prostheses should be designed to minimize negative effects of movement of the connective tissues across the implant surface, e.g. comprising a smooth, atraumatic, low-friction material, coating or surface treatment. Such prostheses could be implanted arthroscopically or using a mini-open or open surgical approach.

[0068] In various alternative embodiments, the displacement portion and the fixation portion of prostheses according to the invention may be of unibody construction, or may be formed of two or more parts depending on desired function. For example, the fixation portion may be stainless steel or titanium textured to enhance bony ingrowth and solid screw fixation, while the displacement portion could be made of a different material, for example, pyrolytic carbon to enhance the ability of overlying tissues to slide across the implant, or PTFE, silicone or other low-friction polymer with suitable wear characteristics to provide a softer bearing surface. In this regard, the displacement portion may comprise a separate bearing member with a bearing surface on which the target tissue bears. Alternatively the bearing surface may be formed as an integral part of the displacement portion. In further alternatives, the displacement portion could be comprised of a substrate of one material with an overlying layer forming the bearing member. The substrate could be either attached to or contiguous with the fixation portion. In other embodiments, the fixation portion of the implant may have a relief feature to minimize contact with the underlying bone, thereby minimizing disruption of the periosteal layer.

[0069] Generally, the bearing member and/or bearing surface in embodiments of the invention will be hard and smooth, made from materials such as polished pyrolytic carbon, steel, or titanium, or coated or covered with a lubricious material, such as PTFE. However, in embodiments where relative motion is provided for within the prosthesis itself, such as in exemplary embodiments described herein below, the bearing surface may be designed to encourage adhesion and ingrowth of the connective tissue onto this surface. For example, such a surface may be porous, roughened, or configured with openings into which bone or scar tissue may grow to enhance adhesion.

[0070] In some embodiments, the implant could be anchored to the underlying bone with suitable fasteners such as screws. Depending on the location and surgical need, unicortical screws, bicortical screws, cancellous screws, cannulated screws, polyaxial screws, screws that lock into the implant etc. may be used. In some embodiments, the screw holes may be locking threads or other locking features. In other embodiments, the screws holes may be oriented in different directions to improve the stability of the anchored implant. In alternate embodiments, different types of screws may be used in different regions of the implant. For example, cortical screws may be used in the region of the implant in contact with the femoral shaft while cancellous screws may be used in another part of the implant in contact with femoral condyle. Depending on patient anatomy and geometry of a specific implant, it may be desirable to provide supplemental fixation (such as cancellous bone screws) in the spanning section.

[0071] As discussed above, joint pain, joint stiffness or joint osteoarthritis may result from cranial tibial translation caused by cruciate ligament disease. By caudally displacing the caudal muscles or tendons like the semitendinosus, semimembranosus or biceps femoris muscle or tendon, the moment arm of the muscle or tendon as it crosses the joint may be increased, thereby stabilizing the joint during the gait cycle. By cranially displacing the cranial muscles or tendons like the quadriceps muscle or tendon, or patellar tendon, the moment arm of the muscle or tendon as it crosses the joint may be increased, thereby stabilizing the joint during the gait cycle. Other muscles and tendons around the knee that contribute to the cranio-caudal stability of the knee may also be displaced to achieve a similar therapeutic effect.

[0072] In one embodiment, displacement of the target tissue results in the decrease in the cranial tibial translation or thrust in the target stifle joint by at least about 0.5mm, more preferably by at least about 1mm, most preferably by at least about 1.5mm. Reduction in cranial translation as defined here refers to decrease in translation, either maximum or average translation, either measured or calculated, during a normal gait cycle, running, jogging or any other physical activity which results in mechanical loading of articular cartilage in a stifle joint.

[0073] As discussed above, Figure 9 shows one exemplary embodiment of the present invention for cranial displacement of the quadriceps muscle or tendon. Implant 100 is anchored to the medial side of the femur. Fixation portion 101 of the implant is used to anchor the implant, e.g. with screws 110, and displacement portion 103 displaces the quadriceps muscle or tendon cranially. Spanning section 102 would be configured to transition from fixation portion 101 mostly parallel to the medial side of the femur to displacement portion 103, which is disposed on a more cranial aspect of the femur so as to displace the quadriceps muscle or tendon cranially.

[0074] Figure 10 shows another exemplary embodiment of the present invention for cranial displacement of the patellar tendon. In this embodiment, implant 200 may be anchored to the medial side of the tibia. Fixation portion 201 of the implant is used to anchor the implant, e.g. with screws, and displacement portion 203 displaces the patellar tendon cranially. Advantageously, the fixation portion is separated from the displacement portion by spanning section 202 so that the fixation portion may be shaped and dimensioned to optimize anchoring, holes 209 for screws may be more numerous and separated further apart, and the location on the bone for anchoring may be more easily accessed and visualized by the surgeon. Displacement portion 203 preferably has a convex curvature on its outer tissue-engaging surface (bearing surface), preferably being curved at least around an axis generally parallel to the tibial shaft, usually being curved also around an axis perpendicular to the tibial shaft, and more preferably being spherical or partially spherical. Displacement portion 203 is disposed over a more cranial aspect of the tibia so as to be located under the patellar tendon between the tendon insertion point and the dorsal end of the tibia.

[0075] In embodiments of the present invention, implants may be configured such that the displacement portion of the implant is separated from the fixation portion of the implant. With the displacement portion positioned under the target tissue (e.g. patellar tendon), the fixation portion of the implant may be configured to be affixed to the bone at a location which can securely fix the implant in place, is accessible to the surgeon, is not covered by the target tissue, and is separated from tendon insertion points and other anatomical features. The implant may have a spanning section configured and dimensioned to bridge the distance between the fixation portion and the displacement portion. The implants may be configured to move the tendon anteriorly or medially or anterior-medially or laterally or antero-laterally. This may be accomplished by making one side (lateral or medial) of the displacement surface higher than the other, and/or by forming a track with ridges on one or both sides of the bearing surface to urge the tendon in a lateral or medial direction.

[0076] Figure 11 shows an exemplary embodiment of the present invention for cranial displacement of the patellar tendon. Implant 300 is anchored to the medial side of the tibia.

[0077] Figure 12 shows an exemplary embodiment of the present invention for cranial displacement of the patellar tendon. Implant 400 is anchored to the lateral side of the tibia.

[0078] Figure 13 shows an exemplary embodiment of the present invention for caudal displacement of the hamstring muscles. Implant 500 is anchored to the medial side of the femur. Implant 500 has a displacement portion configured to be located along a caudal aspect of the femur under the hamstring muscle so as to displace the hamstring caudally, that is, away from the femoral shaft.

[0079] Figure 14 shows an exemplary embodiment of the present invention for caudal displacement of the hamstring muscles. Implant 600 is anchored to the medial side of the tibia.

[0080] Figure 15 shows an exemplary embodiment of the present invention for caudal displacement of the hamstring muscles. Implant 700 is anchored to the lateral side of the femur.

[0081] Figure 16 shows an exemplary embodiment of the present invention for caudal displacement of the hamstring muscles. Implant 800 is anchored to the medial side of the femur.

[0082] Figure 17 shows an exemplary embodiment of the present invention for caudal displacement of the hamstring muscles. Implant 900 is anchored to the lateral side of the femur.

[0083] Figure 18 shows an exemplary embodiment of the present invention for caudal displacement of the hamstring muscles. Implant 1000 is anchored to the medial side of the tibia.

[0084] Figure 19 shows an exemplary embodiment of the present invention for cranial displacement of the patellar tendon. Implant 1100 is anchored to the lateral side of the tibia.

[0085] Figure 20 shows an exemplary embodiment of the present invention for cranial displacement of the quadriceps muscle or tendon. Implant 1200 is anchored to the lateral side of the femur.

[0086] As with other embodiments described herein, the displacement of the target tissue can be altered by changing the length, curvature and angle of the spanning section and/or dimensions of the displacement and fixation portions as appropriate for specific canine anatomy.

[0087] The spanning sections may also comprise adjustable mechanisms (e.g. a pin or hinge) to movably or pivotably alter the orientation or angle between the two parts to achieve the appropriate level of tissue displacement.

[0088] In some embodiments of the present invention, the displacement of the connective tissue could be adjusted by adjusting the device pre-operatively, intra-

operatively or post-operatively. Devices may include mechanisms that are remotely controlled and/or enable wireless communication to alter the displacement after implantation. Alternatively, the displacement may be adjusted by applying an energy fields (e.g.; magnetic field, electric field, thermal field etc.) transdermally from an external location.

[0089] In various adjustable embodiments described above, the adjustment mechanisms themselves may be radiopaque and/or otherwise discernable from the rest of the implant under x-ray in order to enable post-surgical percutaneous adjustment of the device. Alternatively, target features can be built into the device to locate the adjustment points without having the screws or adjustment means themselves radiopaque, such as radiopaque rings or markers built into the bearing surface of the device itself.

[0090] The implants described above may be implanted in areas adjacent to the joint such that the soft tissue is displaced in a region it crosses the joint. Alternatively, the device could be implanted away from the joint and displace the target soft tissue in a region that it is not crossing the joint.

[0091] In other alternative embodiments, displacement portions of previously described static implants may be provided with a roller or other dynamic feature to further reduce wear or trauma to the displaced tissue. In some embodiments, the inferior surface of the displacement region is elevated off the underlying tissue. The underlying tissue could be bone or soft tissue like tendon, muscle, ligament, bursa, capsule etc. Elevating the inferior surface off the underlying tissue could be beneficial by minimizing damage to soft tissue, reducing any potential restriction to joint motion due to compression of soft tissue etc.

[0092] In some embodiments, the displacement region will have a continuous bearing surface which is in contact with the target connective tissue (muscle, tendon, ligament etc.) and is devoid of any discontinuities. Discontinuities would include fixation channels for long-term fixation like screw holes, holes for sutures etc. as well as fixation channels for temporary fixation like holes for Kirschner-wires (K-wires). The lack of discontinuities in the bearing surface would minimize the potential for wear or irritation

of the target connective tissue. The bearing surface of the displacement section may be polished, coated or modified in other ways to minimize wear of the bearing surface and/or wear of the target connective tissue.

[0093] In some embodiments, the bearing surface of the displacement region which is in contact with the target connective tissue (muscle, tendon, ligament etc.) may have features that enable adhesion or attachment of the target connective tissue to the bearing surface. Attachment of the target connective tissue on the implant surface may minimize motion of the tissue across the implant surface during joint motion. These features would include channels for formation of fibrous tissue from the target connective tissue anchoring the connective tissue to the displacement surface of the implant.

[0094] In some embodiments, the bearing surface of the displacement region may have surface features that enable adhesion or attachment of the target connective tissue to the bearing surface. These features would include projections, microprojections, bumps, ridges, pin-like projections, granular surface etc.

[0095] In some embodiments, the inferior surface of the displacement region may be in contact with the underlying tissue. In other embodiments, part of the inferior surface of the displacement section may be in contact with the underlying tissue.

[0096] In some embodiments, the inferior region may have features like channels for fibrous or bony tissue ingrowth to enable adhesion or attachment of the underlying tissue to the bearing surface. In other embodiments, the inferior region may have features like projections, microprojections, bumps, ridges, pin-like projections, granular surface etc. Attachment of any soft connective tissue underneath the inferior surface of the displacement region may minimize motion of the tissue under the implant during joint motion. In other embodiments, the inferior surface may have pins for anchoring the implanting into underlying bone.

[0097] In some embodiments, the device may be a two-part device with the first part (base unit) comprising the fixation section, the spanning section and the displacement section, and the second part (bearing unit) configured to attach to the displacement

section of the base unit. In other embodiments the bearing unit may be configured to attach to the spanning section and to cover the displacement section of the base unit. The bearing unit may be configured to minimize tissue wear or to enable tissue adhesion or attachment. In one embodiment, the displacement section and the bearing unit would have features to attach the two units.

[0098] In some embodiments, the displacement region may have channels to assist in positioning, placement or temporarily anchoring of the implant intra-operatively.

[0099] As will be evident to one skilled in the art, the dimensions of the exemplary embodiments above can be altered to address differences in joint size, condyle size, level of the tissue displacement etc. as well as to enable positioning and securing the implant at the surgical site while minimizing trauma to the surrounding bone, tendons, muscles, ligaments and other anatomical structures.

[00100] While the invention has been illustrated by examples in various contexts, the devices of the present invention may be used to displace any of the muscles and connective tissues around the stifle joint to achieve a therapeutic effect. For example, the muscle displaced could be the popliteus muscle, gastrocnemius muscle, vastus lateralis muscle, vastus medialis muscle and the semimembranous muscle. Alternatively, the tendon associated with any of the muscles could be displaced.

[00101] While the invention has been illustrated by examples in various contexts of treating canine cruciate ligament disease, it will be understood that the invention may also have application to treatment of other animals like cats, horses etc.

[00102] Exemplary embodiments have been disclosed above and illustrated in the accompanying drawings. It will be understood by those skilled in the art that various changes, omissions and additions may be made to that which is specifically disclosed herein without departing from the spirit and scope of the present invention.

CLAIMS

1. A method for treating canine cruciate ligament disease, comprising:
 - securing an implant to one of the canine femur or tibia; and
 - reducing cranial tibial thrust by displacing connective tissue or muscle acting on the canine stifle joint with said implant.
2. The method of claim 1, wherein:
 - said securing comprises securing the implant to the femur; and
 - said reducing comprises displacing the quadriceps tendon cranially with the implant such that the tibial thrust is reduced.
3. The method of claim 1, wherein:
 - said securing comprises securing the implant to the femur; and
 - said reducing comprises displacing the hamstring muscles caudally with the implant such that the tibial thrust is reduced.
4. The method of claim 1, wherein:
 - said securing comprises securing the implant to the tibia; and
 - said reducing comprises displacing the hamstring muscles caudally with the implant such that the tibial thrust is reduced.
5. The method of claim 1, wherein the displacing is greater than about 2 mm up to about 25 mm beyond the natural anatomical track of the target tissue .
6. The method of claim 5, wherein said displacing is in the range of about 4-15 mm.
7. A device for treating canine cruciate ligament disease, comprising:
 - an implant configured and dimensioned to be secured to one of the canine femur or tibia and to extend under a target tissue, the target tissue comprising at least one connective tissue or muscle of the stifle joint, to displace said target tissue sufficiently to reduce cranial tibial thrust.
8. The device of claim 7, wherein said implant comprises:
 - a fixation portion configured to be secured to one said bone; and

- a displacement portion extending from the fixation portion and configured to atraumatically contact and displace said target tissue.
9. The device of claim 8, wherein the displacement portion includes a bearing surface comprising a smooth surface free of discontinuities to atraumatically engage and displace the target tissue.
 10. The device of claim 9, further comprising a spanning section disposed between the fixation portion and displacement portion.
 11. The device of claim 10, wherein:
 - the fixation portion is configured and dimensioned to be secured to the femur; and
 - the spanning section and displacement portion are configured and dimensioned to position the bearing surface in engagement with the quadriceps tendon to displace said tendon cranially.
 12. The device of claim 10, wherein:
 - the fixation portion is configured and dimensional to be secured to the femur; and
 - the spanning section and displacement portion are configured to position the bearing surface in engagement with the hamstring muscles to displace said muscles caudally.
 13. The device of claim 10, wherein:
 - the fixation portion is configured and dimensioned to be secured to the tibia; and
 - the spanning section and displacement portion are configured to position the bearing surface in engagement with the hamstring muscles to displace said muscles caudally.
 14. The device of claim 10, wherein the spanning section and displacement portion are configured and dimensioned to position the bearing surface so as to displace the target tissue greater than about 2 mm up to about 25 mm beyond the natural anatomical track of the target tissue.

15. The device of claim 14, wherein said displacement is the range of about 4-15 mm.




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9




FIG. 10




FIG. 11




FIG. 12




FIG. 13




FIG. 14




FIG. 15




FIG. 16




FIG. 17




FIG. 18




FIG. 19




FIG. 20

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2013/058877

<p>A. CLASSIFICATION OF SUBJECT MATTER IPC(8) - A61B 17/56 (2013.01) USPC - 606/286 According to International Patent Classification (IPC) or to both national classification and IPC</p>														
<p>B. FIELDS SEARCHED</p> <p>Minimum documentation searched (classification system followed by classification symbols) IPC(8) - A61B 17/56, 17/58; A61F 2/08, 2/30, 2/38 (2013.01) USPC - 424/423; 606/286; 623/13.14, 20.14</p> <p>Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched CPC - A61F 2002/30703 (2013.01)</p> <p>Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) PatBase, Google Patents</p>														
<p>C. DOCUMENTS CONSIDERED TO BE RELEVANT</p> <table border="1"> <thead> <tr> <th>Category*</th> <th>Citation of document, with indication, where appropriate, of the relevant passages</th> <th>Relevant to claim No.</th> </tr> </thead> <tbody> <tr> <td>X</td> <td>US 2011/0230919 A1 (ALLEYNE) 22 September 2011 (22.09.2011) entire document</td> <td>1, 5-10, 14, 15</td> </tr> <tr> <td>Y</td> <td></td> <td>2-4, 11-13</td> </tr> <tr> <td>Y</td> <td>US 2011/0202138 A1 (SHENOY et al) 18 August 2011 (18.08.2011) entire document</td> <td>2-4, 11-13</td> </tr> </tbody> </table>			Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	X	US 2011/0230919 A1 (ALLEYNE) 22 September 2011 (22.09.2011) entire document	1, 5-10, 14, 15	Y		2-4, 11-13	Y	US 2011/0202138 A1 (SHENOY et al) 18 August 2011 (18.08.2011) entire document	2-4, 11-13
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.												
X	US 2011/0230919 A1 (ALLEYNE) 22 September 2011 (22.09.2011) entire document	1, 5-10, 14, 15												
Y		2-4, 11-13												
Y	US 2011/0202138 A1 (SHENOY et al) 18 August 2011 (18.08.2011) entire document	2-4, 11-13												
<p><input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/></p>														
<p>* Special categories of cited documents:</p> <table border="0"> <tr> <td>“A” document defining the general state of the art which is not considered to be of particular relevance</td> <td>“T” later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>“E” earlier application or patent but published on or after the international filing date</td> <td>“X” document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>“L” document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>“Y” document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>“O” document referring to an oral disclosure, use, exhibition or other means</td> <td>“&” document member of the same patent family</td> </tr> <tr> <td>“P” document published prior to the international filing date but later than the priority date claimed</td> <td></td> </tr> </table>			“A” document defining the general state of the art which is not considered to be of particular relevance	“T” later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	“E” earlier application or patent but published on or after the international filing date	“X” document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	“L” document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	“Y” document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	“O” document referring to an oral disclosure, use, exhibition or other means	“&” document member of the same patent family	“P” document published prior to the international filing date but later than the priority date claimed			
“A” document defining the general state of the art which is not considered to be of particular relevance	“T” later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention													
“E” earlier application or patent but published on or after the international filing date	“X” document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone													
“L” document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	“Y” document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art													
“O” document referring to an oral disclosure, use, exhibition or other means	“&” document member of the same patent family													
“P” document published prior to the international filing date but later than the priority date claimed														
<p>Date of the actual completion of the international search 18 December 2013</p>		<p>Date of mailing of the international search report 09 JAN 2014</p>												
<p>Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US, Commissioner for Patents P.O. Box 1450, Alexandria, Virginia 22313-1450 Facsimile No. 571-273-3201</p>		<p>Authorized officer: Blaine R. Copenheaver PCT Helpdesk: 571-272-4300 PCT OSP: 571-272-7774</p>												